PROCEPT BioRobotics: Hold Rating Amid Strong Revenue but Concerns Over Utilization and Sales Cycles
I'm PortAI, I can summarize articles.
Ryan Zimmerman has assigned a Hold rating to PROCEPT BioRobotics, citing strong revenue growth but concerns over handpiece utilization and declining average selling prices. The new CEO emphasizes the need for improved utilization, while management's comments on longer sales cycles and inventory adjustments have led to a cautious outlook. Preliminary revenue guidance suggests potential downward adjustments to estimates. Despite a decrease in valuation, concerns about slowing utilization and high expectations persist, prompting the Hold rating. TR | OpenAI – 4o also reiterated a Hold rating with a $35.00 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments